-$0.43 EPS Expected for Nurix Therapeutics, Inc. (NASDAQ:NRIX) This Quarter


Share on StockTwits

Brokerages expect Nurix Therapeutics, Inc. (NASDAQ:NRIX) to announce ($0.43) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Nurix Therapeutics’ earnings, with estimates ranging from ($0.49) to ($0.34). The firm is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Nurix Therapeutics will report full year earnings of ($1.57) per share for the current year, with EPS estimates ranging from ($1.90) to ($1.34). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.57) per share, with EPS estimates ranging from ($1.86) to ($1.14). Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Nurix Therapeutics.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Tuesday, February 16th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.02. The company had revenue of $6.69 million for the quarter, compared to the consensus estimate of $5.41 million.

A number of research firms have recently issued reports on NRIX. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, February 17th. JPMorgan Chase & Co. boosted their price target on shares of Nurix Therapeutics from $34.00 to $56.00 and gave the stock an “overweight” rating in a research note on Friday, January 29th. Piper Sandler boosted their price target on shares of Nurix Therapeutics from $40.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 17th. Finally, Zacks Investment Research raised shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 15th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $46.80.

NASDAQ NRIX opened at $33.62 on Monday. Nurix Therapeutics has a 52-week low of $15.21 and a 52-week high of $52.38. The company has a fifty day moving average of $35.63 and a 200-day moving average of $35.14.

In related news, CFO Houte Hans Van sold 5,330 shares of the business’s stock in a transaction dated Monday, February 22nd. The shares were sold at an average price of $39.93, for a total transaction of $212,826.90. Following the transaction, the chief financial officer now owns 1,417 shares in the company, valued at $56,580.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Christine Ring sold 2,000 shares of the business’s stock in a transaction dated Wednesday, March 10th. The shares were sold at an average price of $41.27, for a total transaction of $82,540.00. The disclosure for this sale can be found here. Insiders have sold 9,730 shares of company stock worth $386,747 in the last quarter.

Institutional investors and hedge funds have recently made changes to their positions in the business. Penserra Capital Management LLC purchased a new stake in Nurix Therapeutics in the fourth quarter worth about $29,000. Pacer Advisors Inc. grew its holdings in Nurix Therapeutics by 193.3% in the first quarter. Pacer Advisors Inc. now owns 1,581 shares of the company’s stock worth $49,000 after purchasing an additional 1,042 shares during the period. Morgan Stanley purchased a new stake in Nurix Therapeutics in the third quarter worth about $60,000. Strs Ohio purchased a new stake in Nurix Therapeutics in the third quarter worth about $97,000. Finally, Citigroup Inc. grew its holdings in Nurix Therapeutics by 559.3% in the fourth quarter. Citigroup Inc. now owns 3,514 shares of the company’s stock worth $116,000 after purchasing an additional 2,981 shares during the period. Institutional investors and hedge funds own 81.99% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Further Reading: Google Finance Portfolio Workaround

Get a free copy of the Zacks research report on Nurix Therapeutics (NRIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.